Stock DNA
Pharmaceuticals & Biotechnology
CNY 9,311 Million (Mid Cap)
14.00
NA
2.44%
-0.19
4.45%
1.74
Revenue and Profits:
Net Sales:
1,824 Million
(Quarterly Results - Dec 2025)
Net Profit:
96 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-34.41%
0%
-34.41%
6 Months
-25.78%
0%
-25.78%
1 Year
-44.17%
0%
-44.17%
2 Years
-50.41%
0%
-50.41%
3 Years
-8.29%
0%
-8.29%
4 Years
22.06%
0%
22.06%
5 Years
17.89%
0%
17.89%
KPC Pharmaceuticals, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-3.14%
EBIT Growth (5y)
-7.48%
EBIT to Interest (avg)
15.66
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.12
Sales to Capital Employed (avg)
1.18
Tax Ratio
20.51%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10.74%
ROE (avg)
10.11%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
2.01
EV to EBIT
11.21
EV to EBITDA
9.02
EV to Capital Employed
2.25
EV to Sales
1.17
PEG Ratio
0.20
Dividend Yield
2.16%
ROCE (Latest)
20.08%
ROE (Latest)
14.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
1,824.00
1,399.90
30.30%
Operating Profit (PBDIT) excl Other Income
49.90
16.90
195.27%
Interest
10.30
12.80
-19.53%
Exceptional Items
-11.70
119.20
-109.82%
Consolidate Net Profit
95.60
73.50
30.07%
Operating Profit Margin (Excl OI)
-0.40%
-24.00%
2.36%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 30.30% vs -19.68% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 30.07% vs -46.11% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
6,537.40
8,341.70
-21.63%
Operating Profit (PBDIT) excl Other Income
442.50
1,008.80
-56.14%
Interest
53.00
28.80
84.03%
Exceptional Items
115.60
4.90
2,259.18%
Consolidate Net Profit
419.10
751.20
-44.21%
Operating Profit Margin (Excl OI)
37.00%
95.80%
-5.88%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -21.63% vs -0.33% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -44.21% vs 16.88% in Dec 2024
About KPC Pharmaceuticals, Inc. 
KPC Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






